MARKET

IBRX

IBRX

Immunitybio Inc
NASDAQ
7.11
-1.53
-17.66%
After Hours: 7.11 0 0.00% 16:07 11/09 EST
OPEN
7.23
PREV CLOSE
8.64
HIGH
7.35
LOW
6.36
VOLUME
44.71M
TURNOVER
--
52 WEEK HIGH
12.43
52 WEEK LOW
1.950
MARKET CAP
7.54B
P/E (TTM)
-7.3367
1D
5D
1M
3M
1Y
5Y
1D
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS) and ImmunityBio (IBRX)
TipRanks · 2h ago
ImmunityBio, Inc. Reports Q3 2026 Net Product Revenue of $48.7 Million and FDA Label Expansion for ANKTIVA
NASDAQ · 3h ago
ImmunityBio falls -18.3%
TipRanks · 4h ago
Midday Fly By: Nvidia investigating CEO following affair with alleged spy
TipRanks · 4h ago
ImmunityBio Reports Wider Quarterly Loss
Benzinga · 5h ago
ImmunityBio falls -22.6%
TipRanks · 6h ago
ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 8h ago
ImmunityBio Reports Expanded ANKTIVA Approval And Global Market Expansion, Expanding ANKTIVA Footprint To 35 Countries
Benzinga · 8h ago
More
About IBRX
ImmunityBio, Inc. is a biotechnology company focused on developing and commercializing immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the goal of restoring immune function and generating lasting immunological memory in patients. The Cancer BioShield platform is designed to stimulate critical lymphocytes, including natural killer (NK) cells, cytotoxic T cells, and memory T cells via its IL-15 receptor agonist, ANKTIVA. The Cancer BioShield platform is anchored by this antibody-cytokine fusion protein and is complemented by a portfolio that includes adenovirus-vectored vaccines, allogeneic (off-the-shelf) and autologous NK-cell therapies, and additional immunomodulators intended to promote immunogenic cell death and support durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapy.

Webull offers Immunitybio Inc stock information, including NASDAQ: IBRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IBRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IBRX stock methods without spending real money on the virtual paper trading platform.